Drug intelligence / Profile preview

YK-CD19-22-Boom

Development stage: Unknown
Lead developer: Shanghai YaKe Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**YK-CD19-22-Boom** is an investigational dual-target chimeric antigen receptor T-cell therapy directed against CD19 and CD22, B-cell lineage antigens expressed on malignant B cells. The product is administered by infusion and is intended to enable engineered T cells to recognize and eliminate CD19-positive and CD22-positive hematologic cancer cells, potentially reducing relapse driven by loss of either single antigen. It was studied by the First Affiliated Hospital, Zhejiang University School of Medicine in a registered Phase 1 clinical study for CD19-positive/CD22-positive hematologic malignancies, including leukemia and lymphoma.

Brand names: BoomTM
Other names: CD19/CD22 CAR-TYaKe Biotechnology CD19/CD22 CAR-T cell therapy

Targets

CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on YK-CD19-22-Boom.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YK-CD19-22-Boom.

Explore the full profile